Association between three genetic variants in kallikrein 3 and prostate cancer risk
暂无分享,去创建一个
Yu Bai | Atsushi Okada | Takahiro Yasui | Yuan-Yuan Mi | T. Yasui | Weihong Ding | A. Okada | Wei-Hong Ding | Ke-Wei Ren | Chuang Yue | Jian-Gang Zou | Li Zuo | Li-Feng Zhang | Yu Bai | Yuan-yuan Mi | Lifeng Zhang | L. Zuo | C. Yue | Jian-gang Zou | Ke-wei Ren
[1] G. Franck. Open access , 2012, Cell cycle.
[2] P. Tugwell,et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .
[3] M. Spitz,et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. , 2000, Journal of the National Cancer Institute.
[4] Jianpeng Hu,et al. Kallikrein 3 and vitamin D receptor polymorphisms: potentials environmental risk factors for prostate cancer , 2014, Diagnostic Pathology.
[5] W. Haenszel,et al. Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.
[6] Ali Amin Al Olama,et al. Multiple newly identified loci associated with prostate cancer susceptibility , 2008, Nature Genetics.
[7] J. Witte,et al. Role of Androgen Metabolism Genes CYP1B1, PSA/KLK3, and CYP11α in Prostate Cancer Risk and Aggressiveness , 2005, Cancer Epidemiology Biomarkers & Prevention.
[8] A. Tsatsoulis,et al. Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. , 2003, European journal of endocrinology.
[9] Z. Szallasi,et al. CAUSEL: An epigenome and genome editing pipeline for establishing function of non-coding GWAS variants , 2015, Nature Medicine.
[10] G. Abecasis,et al. Heritability of Cardiovascular and Personality Traits in 6,148 Sardinians , 2006, PLoS genetics.
[11] S. Hamilton-Dutoit,et al. Comparative analysis of three- and two-antibody cocktails to AMACR and basal cell markers for the immunohistochemical diagnosis of prostate carcinoma , 2012, Diagnostic Pathology.
[12] A. Chokkalingam,et al. Molecular epidemiology of prostate cancer: hormone-related genetic loci. , 2007, Frontiers in bioscience : a journal and virtual library.
[13] Jack A. Taylor,et al. Genetic polymorphism and prostate cancer aggressiveness: A case‐only study of 1,536 GWAS and candidate SNPs in African‐Americans and European‐Americans , 2013, The Prostate.
[14] J. Clements,et al. Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. , 2010, Endocrine reviews.
[15] Eleftherios P. Diamandis,et al. The New Human Kallikrein Gene Family: Implications in Carcinogenesis , 2000, Trends in Endocrinology & Metabolism.
[16] Chen Chen,et al. Single-nucleotide polymorphism rs1058205 of KLK3 is associated with the risk of prostate cancer , 2017, Medicine.
[17] W. Catalona,et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.
[18] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[19] A. Gylfason,et al. Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels , 2010, Science Translational Medicine.
[20] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[21] Jianfeng Xu,et al. Systematic enrichment analysis of potentially functional regions for 103 prostate cancer risk‐associated loci , 2015, The Prostate.
[22] A. Meikle,et al. Heritability of prostate-specific antigen and relationship with zonal prostate volumes in aging twins. , 2000, The Journal of clinical endocrinology and metabolism.
[23] Genome-wide association study identified novel genetic variant on SLC45A3 gene associated with serum levels prostate-specific antigen (PSA) in a Chinese population , 2013, Human Genetics.
[24] Peter Kraft,et al. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. , 2011, Carcinogenesis.
[25] T. Sellers,et al. A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. , 2015, Cancer discovery.
[26] D. English,et al. Variants in the Prostate-Specific Antigen (PSA) Gene and Prostate Cancer Risk, Survival, and Circulating PSA , 2006, Cancer Epidemiology Biomarkers & Prevention.
[27] J. Carpten,et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. , 2007, Journal of the National Cancer Institute.
[28] H. Grönberg,et al. Association of Prostate Cancer Risk Variants with Clinicopathologic Characteristics of the Disease , 2008, Clinical Cancer Research.
[29] Liang Sun,et al. Susceptibility loci associations with prostate cancer risk in northern Chinese men. , 2013, Asian Pacific journal of cancer prevention : APJCP.
[30] Miltiadis Paliouras,et al. Human tissue kallikreins: the cancer biomarker family. , 2007, Cancer letters.
[31] C. P. Morris,et al. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. , 2006, Carcinogenesis.
[32] Linlin Zhang,et al. rs10505474 and rs7837328 at 8q24 cumulatively confer risk of prostate cancer in Northern Han Chinese. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[33] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[34] J. Ioannidis. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. , 1998, JAMA.
[35] J. Witte,et al. Role of Androgen Metabolism Genes CYP 1 B 1 , PSA / KLK 3 , and CYP 11 a in Prostate Cancer Risk and Aggressiveness , 2005 .
[36] Nilanjan Chatterjee,et al. Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels , 2011, Human Genetics.
[37] Tsuguya Fukui,et al. Systematic Evaluation and Comparison of Statistical Tests for Publication Bias , 2005, Journal of epidemiology.
[38] F. Hamdy,et al. Screening for Prostate Cancer , 2006 .
[39] G. Yousef,et al. Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. , 1999, Anticancer research.